search
Back to results

FDG Metabolism in Dementia With Lewy Body (DLB) Patients as Indicated by PET Dynamic Acquisition

Primary Purpose

Dementia With Lewy Bodies

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PET-CT FDG brain scan
Sponsored by
Tel-Aviv Sourasky Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Dementia With Lewy Bodies

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A cohort of healthy patients with no symptoms or family history of DLB will be tested as control group.
  2. Healthy asymptomatic patients with first-degree relatives of DLB patients.
  3. DLB patients that went through comprehensive neuropsychological assessments and were confirmed as suffering from DLB.

Exclusion Criteria:

  1. Age <18.
  2. Pregnant or breath feeding patients.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Dementia with Lewy Body (DLB) patients

    Arm Description

    Outcomes

    Primary Outcome Measures

    number of patients that have shown the tracer time activity curve between healthy, DLB and AD patients for differential diagnosis.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 29, 2019
    Last Updated
    November 4, 2019
    Sponsor
    Tel-Aviv Sourasky Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04154215
    Brief Title
    FDG Metabolism in Dementia With Lewy Body (DLB) Patients as Indicated by PET Dynamic Acquisition
    Official Title
    FDG Metabolism in Dementia With Lewy Body (DLB) Patients as Indicated by PET Dynamic Acquisition
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 14, 2019 (Anticipated)
    Primary Completion Date
    January 14, 2020 (Anticipated)
    Study Completion Date
    December 14, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Tel-Aviv Sourasky Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Dementia with Lewy Body (DLB) is a common neurodegenerative disorder responsible to 15%-20% of the dementia cases in the elderly population. Dementia with Lewy Body (DLB) is a common neurodegenerative disorder responsible to 15%-20% of the dementia cases in the elderly population . This disorder belongs to the family of synucleinopathies, which are diseases characterized by the abnormal accumulation of the protein α-synuclein (α-syn) in neuronal and non-neuronal cells in the brain. The clinical symptoms of DLB include dementia with the presence of fluctuations in attention or alertness, recurrent visual hallucinations, spontaneous extrapyramidal motor features and REM sleep behavior disorder (RBD). Supportive clinical symptoms are severe sensitivity to antipsychotic agents, postural instability, repeated falls, syncope or other transient episodes of unresponsiveness, severe autonomic dysfunction e.g. constipation, orthostatic hypotension, urinary incontinence, hypersomnia, hyposmia, hallucinations in other modalities, systematized delusions, apathy, anxiety and depression. DLB differs from PD by the order of appearance of clinical symptoms. The diagnosis of DLB requires in addition to the clinical symptoms the existence biomarkers indicating the pathology. It is important to note that due to the complexity of DLB diagnosis, mainly due to the similarity of this syndrome to other dementia conditions, more than one biomarker is required to identify DLB [6]. The biomarkers contain indicative biomarkers and supportive biomarkers. Indicative biomarkers include a. Assessment of the integrity of dopaminergic system by either F-DOPA Positron Emission Tomography (PET) or by Ioflupane 123I (DaT) Single Photon Emission Tomography (SPECT) scans. b. Abnormal (low uptake) MIBG myocardial scintigraphy. c. Polysomnographic confirmation of REM sleep without atonia. Supportive biomarkers are: a. MRI/CT scans showing neuronal structural modifications with relative preservation of medial temporal lobe structures. b. Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity +/- the cingulate island sign on 18F-fludeoxyglucose (FDG) PET imaging. c. Prominent posterior slow wave activity on EEG with periodic fluctuations in the pre-alpha/theta range. Biochemical biomarkers from the blood and spinal fluid were also investigated. These biomarkers include measurement of levels of Amyloid β, tau, and phospho-tau measurements. However, they do not allow differentiation between DLB and AD. α-syn was not proven as a biomarker.
    Detailed Description
    The purpose of this research is to assess whether dynamic FDG-PET scans and quantitative analysis of the these scans can give a more accurate and sensitive information regarding the DLB brain glucose metabolism which in turn may give better insight about DLB mechanism and allow better assessment of the disease. Glucose metabolism in the brains of DLB patients is characterized by a pattern of bilateral parietal and posterior temporal hypometabolism with specific occipital hypo metabolic signature [9]. The use of FDG-PET scans allows the mapping of the topographic hypo metabolic view of the brain in different stages of the DLB condition. These metabolic maps, in turn, can be used both for diagnostic purposes as well as for research of the DLB mechanism [10] [11]. FDG is also a modality assisting in the differentiation between AD, PD and DLB [12]. To notice, the disadvantage of the FDG-PET scans is the lack of quantification. Visually analysis of brain FDG metabolism without quantitative analysis is limiting its use as a biomarker and the diagnostic accuracy and sensitivity of the scan. This is the main reason why it is considered only a supportive biomarker [9]. In these study the investigators will investigate the utilization of dynamic FDG PET scans in order to track in more close and precise way the path of the glucose metabolism in the brain. In addition, the investigators would like to use the dynamic scans to perform quantification of the FDG distribution in the brain in order to show the advantage of the quantification in the diagnostic process.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Dementia With Lewy Bodies

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Dementia with Lewy Body (DLB) patients
    Arm Type
    Experimental
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    PET-CT FDG brain scan
    Intervention Description
    Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan. The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration. After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated.
    Primary Outcome Measure Information:
    Title
    number of patients that have shown the tracer time activity curve between healthy, DLB and AD patients for differential diagnosis.
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    120 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A cohort of healthy patients with no symptoms or family history of DLB will be tested as control group. Healthy asymptomatic patients with first-degree relatives of DLB patients. DLB patients that went through comprehensive neuropsychological assessments and were confirmed as suffering from DLB. Exclusion Criteria: Age <18. Pregnant or breath feeding patients.

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    FDG Metabolism in Dementia With Lewy Body (DLB) Patients as Indicated by PET Dynamic Acquisition

    We'll reach out to this number within 24 hrs